Daraxonrasib in Pancreatic Cancer: A Generational Shift in Treatment?
247 Health News Editorial
·13 July 2026
·3 min read
·healthtechDaraxonrasib has produced pancreatic cancer trial results that leading oncologists are comparing to the arrival of the first checkpoint inhibitors — a potential generational shift in a disease with historically dismal outcomes. Clinicians managing PDAC should act now to review molecular testing pathways and monitor imminent peer-reviewed data.
Originally reported by STAT News
References
- 1.Joseph, A. (2026, July 13). A breakthrough in pancreatic cancer has experts excited — and braced for what's to come. STAT News. https://www.statnews.com/2026/07/13/pancreatic-cancer-daraxonrasib-opportunities-challenges/
- 2.Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12–49. https://doi.org/10.3322/caac.21820
- 3.Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J. L., & Bachet, J. B. (2018). FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. New England Journal of Medicine, 379(25), 2395–2406. https://doi.org/10.1056/NEJMoa1809775
- 4.Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., & Christensen, J. G. (2020). The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discovery, 10(1), 54–71. https://doi.org/10.1158/2159-8290.CD-19-1167
- 5.Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021). Estimated projection of US cancer incidence and death to 2040. JAMA Network Open, 4(4), e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708
- 6.Prasad, V., Vandross, A., Toomey, C., Cheung, M., Rho, J., Quinn, S., & Cifu, A. (2013). A decade of reversal: An analysis of 146 contradicted medical practices. Mayo Clinic Proceedings, 88(8), 790–798. https://doi.org/10.1016/j.mayocp.2013.05.012
- 7.Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., & Jänne, P. A. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine, 384(25), 2371–2381. https://doi.org/10.1056/NEJMoa2103695
- 8.Cancer Council Australia Oncology Guidelines Working Party. (2023). Clinical practice guidelines for the management of pancreatic cancer. Cancer Council Australia. https://www.cancer.org.au/health-professionals/clinical-guidelines/pancreatic-cancer
2
247 Health News Editorial
247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service